CollPlant Biotechnologies Ltd. (OPHI)
| Market Cap | 7.09M |
| Revenue (ttm) | 318,000 -86.8% |
| Net Income | -12.51M |
| EPS | -9.32 |
| Shares Out | 1.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 67,507 |
| Open | 4.100 |
| Previous Close | 4.640 |
| Day's Range | 3.600 - 4.280 |
| 52-Week Range | 2.637 - 22.500 |
| Beta | 0.57 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About OPHI
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue mat... [Read more]
Full Company ProfileFinancial Performance
In 2025, CollPlant Biotechnologies's revenue was $2.37 million, an increase of 360.39% compared to the previous year's $515,000. Losses were -$11.49 million, -30.83% less than in 2024.
Financial StatementsNews
CollPlant to Begin Trading on Nasdaq Under New Ticker Symbol “OPHI”
OPHI marks another important step in CollPlant's strategy to expand and focus its operations built around LightSolver's all-optical Laser Processing Unit (LPU)™ OPHI marks another important step in Co...
LightSolver to Unveil the First Public Demonstration of its All-Optical Computer at SC26
Rehovot, Israel, Nov. 11, 2026 (GLOBE NEWSWIRE) -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced that its subsidiary LightSolver Ltd.
LightSolver Secures ~$1.8 Million Grant from Israel's Innovation Authority to Advance its Laser Processing Unit (LPU)
Government-backed R&D program to advance next-generation LPU hardware and expand the LPU Lab platform Builds on LightSolver's recent commercial and technical momentum, including the strategic partners...
CollPlant Announces Proposed Name Change to OptiPhi Computing Reflecting Expansion to Computing with Light
Rehovot, Israel, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced that its Board of Directors has approved a proposal to change the Company's name to Opt...
LightSolver Secures Paid Collaboration with the Israel Ministry of Defense for the Development of Photonic Computing Technology
Rehovot, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced that its subsidiary LightSolver Ltd.
COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT
Transaction Led Primarily by Existing Investors to Accelerate LightSolver's Laser-Based Supercomputing Development REHOVOT, Israel, Oct. 9, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN...
LightSolver Files U.S. Provisional Patent Application Expanding its Photonic Computing Platform to Advanced Scientific and Engineering Simulations
CollPlant Advances its Photonic Computing Strategy Through LightSolver's Growing IP Portfolio REHOVOT, Israel, Oct. 6, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announce...
COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Strategic Expansion into Photonic Computing via LightSolver Acquisition Diversifies Technology Portfolio Alongside Continued Innovations in Regenerative Medicine REHOVOT, Israel, Sept. 30, 2026 /PRNew...
CollPlant Biotechnologies Earnings release: Q2 2026
CollPlant Biotechnologies released its Q2 2026 earnings on September 30, 2026, summarizing the period's financial results.
LightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC Workloads
Peer-reviewed study published by ACM: LightSolver's LPU architecture demonstrated significantly lower projected time-to-solution, compared to state-of-the-art algorithms running on a GPU REHOVOT, Isra...
CollPlant Regains Compliance with Nasdaq Minimum Bid Price Requirement
Nasdaq confirms the Company satisfies continued listing criteria under Listing Rule 5550(a)(2), officially closing the compliance matter Follows the recent completion of the LightSolver acquisition, m...
CollPlant Biotechnologies Transcript: Investor update
A strategic acquisition introduces a disruptive all-optical computing platform targeting the $89B HPC market, with a performance-driven deal structure and strong customer validation, including Boeing. Commercialization is underway, with product launch targeted for 2028.
CollPlant Biotechnologies Slides: Investor update
CollPlant Biotechnologies has posted slides in relation to its latest quarterly earnings report, which was published on September 17, 2026.
CollPlant to Host LightSolver Investor Webinar on September 17, 2026
REHOVOT, Israel, Sept. 10, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd.
COLLPLANT APPOINTS DR. RUTI BEN SHLOMI TO ITS BOARD OF DIRECTORS FOLLOWING CLOSING OF LIGHTSOLVER ACQUISITION
LightSolver Founder and CEO brings deep scientific and entrepreneurial expertise to CollPlant's Board as the Company advances the commercialization of its newly acquired photonic computing technology ...
COLLPLANT COMPLETES ACQUISITION OF LIGHTSOLVER, ENTERING THE PHOTONIC COMPUTING SECTOR
Technological Edge - LightSolver advances the development of the world's first Laser Processing Unit (LPU) – an energy-efficient, pure photonic computing platform Accelerated Growth Path - The transac...
COLLPLANT ANNOUNCES REVERSE SHARE SPLIT
REHOVOT, Israel, Sept. 1, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd.
COLLPLANT IS ACQUIRING LIGHTSOLVER- ENTERS SUPERCOMPUTING AND PHOTONIC COMPUTING MARKETS
LightSolver is pioneering pure photonic computing, bringing a new computing architecture to the public markets to address the speed, energy and heat limitations of semiconductor-based computing LightS...
CollPlant Biotechnologies Registration statement: Registration filing
CollPlant Biotechnologies filed a registration statement on July 9, 2026, providing details about a securities offering with the SEC.
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT
REHOVOT, Israel, June 30, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non...
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
REHOVOT, Israel, May 29, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and medical aesthetics company developing innovative technologies and products based on its non-a...
CollPlant Biotechnologies Earnings release: Q1 2026
CollPlant Biotechnologies released its Q1 2026 earnings on May 29, 2026, summarizing the period's financial results.
CollPlant Biotechnologies Registration statement: Registration filing
CollPlant Biotechnologies filed a registration statement on April 15, 2026, providing details about a securities offering with the SEC.
CollPlant Issues Letter to Shareholders
REHOVOT, Israel, April 13, 2026 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary plant-...
CollPlant Biotechnologies Registration statement: Registration filing
CollPlant Biotechnologies filed a registration statement on March 30, 2026, providing details about a securities offering with the SEC.